|Assessment Status||Rapid review complete|
|Indication||For the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.|
|Rapid review commissioned||19/04/2017|
|Rapid review completed||26/04/2017|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.